Skip to main content
    O

    Ovid Therapeutics Inc (OVID)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.40
    -0.14 (-5.51%)

    Market Cap: $479.38M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Ovid Therapeutics Inc (OVID) Financials: Revenue, Profit and Cash Flow

    Updated Nov 10, 2026. Financial statements from company filings, amounts in US dollars.

    Ovid Therapeutics reported revenue of $7.25M for the fiscal year ended Dec 31, 2025, up 1181.3% from the year before. That year, net income was -$17.41M with a net margin of -240.1%, operating cash flow was -$38.33M and free cash flow was -$38.33M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$20.78M.

    Revenue and Margins

    Over the 5 years to Dec 2025, revenue fell from $12.62M, a compound annual decline of 10.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$7.25M+1181.3%100.0%-585.2%-240.1%
    Dec 2024$566.00K+44.4%100.0%-10933.7%-4670.1%
    Dec 2023$392.00K-73.9%100.0%-15122.7%-13351.8%
    Dec 2022$1.50M-99.3%100.0%-3696.4%-3604.7%
    Dec 2021$208.38M+1551.6%100.0%59.6%58.9%
    Dec 2020$12.62MN/A100.0%-645.4%-642.3%
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$7.25M$566.00K$392.00K$1.50M$208.38M$12.62M$0$0$0$0
    Gross profit$7.25M$566.00K$392.00K$1.50M$208.38M$12.62M$0$0$0$0
    Research and development$25.58M$36.77M$28.59M$24.62M$46.94M$63.42M$42.16M$33.79M$49.97M$9.59M
    Operating income-$42.44M-$61.88M-$59.28M-$55.55M$124.21M-$81.43M-$61.41M-$52.93M-$65.01M-$22.54M
    Net income-$17.41M-$26.43M-$52.34M-$54.17M$122.83M-$81.04M-$60.46M-$51.98M-$64.81M-$22.41M
    EBITDA-$15.95M-$24.72M-$50.74M-$52.79M$124.40M-$80.73M-$60.21M-$52.79M-$64.93M-$22.48M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$733.00K$0$718.00K$132.00K$6.27M$130.00K$76.00K$173.00K$169.00K$148.00K$142.00K
    Gross profit$0$733.00K$0$718.00K$132.00K$6.27M$130.00K$76.00K$173.00K$169.00K$148.00K$142.00K
    Operating income-$22.36M-$15.70M-$17.85M-$12.29M-$12.52M-$5.07M-$12.55M-$10.72M-$13.23M-$20.52M-$17.42M-$18.19M
    Net income-$20.78M-$15.01M-$16.99M$9.66M-$12.16M-$4.68M-$10.23M-$9.25M-$14.01M$8.52M-$11.69M-$15.32M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.43M by $11.72M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$150.93M$92.17M$144.03M$155.27M$194.54M$75.93M$80.84M$47.65M$89.46M$53.03M
    Current assets$74.37M$55.94M$109.60M$131.38M$190.48M$74.84M$79.81M$44.27M$88.59M$52.41M
    Cash and equivalents$13.15M$26.30M$27.04M$44.87M$187.80M$72.03M$41.90M$36.49M$87.13M$51.94M
    Total liabilities$20.27M$23.94M$56.23M$22.99M$14.80M$32.29M$10.82M$8.84M$6.02M$3.73M
    Short-term debt$1.43M$1.34M$1.25M$533.95KN/AN/AN/AN/AN/AN/A
    Shareholder equity$130.66M$68.23M$87.80M$132.27M$179.75M$43.63M$70.02M$38.81M$83.44M$49.29M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$222.24M$231.97M$225.63M$150.93M$63.85M$77.43M$81.65M$92.17M$102.65M$118.09M$131.61M$144.03M
    Total liabilities$23.57M$22.08M$27.36M$20.27M$19.15M$21.64M$22.38M$23.94M$26.36M$29.19M$53.33M$56.23M
    Cash and equivalents$13.81M$11.33M$94.06M$13.15M$20.61M$28.41M$21.14M$26.30M$15.02M$29.69M$30.77M$27.04M
    Shareholder equity$198.67M$209.89M$198.27M$130.66M$44.70M$55.79M$59.28M$68.23M$76.29M$88.90M$78.28M$87.80M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$38.33M-$55.96M-$45.78M-$55.23M$118.61M-$51.58M-$51.09M-$45.56M-$31.47M-$17.80M
    Capital expenditures$0$161.00K$137.00K$1.42M$189.41K$390.68K$244.04K$352.02K$47.39K$188.99K
    Free cash flow-$38.33M-$56.12M-$45.92M-$56.65M$118.42M-$51.97M-$51.33M-$45.91M-$31.52M-$17.99M
    Share repurchasesN/AN/AN/AN/A$21.31K$163.25K$0N/A$3.07M$13.67K
    Investing cash flow-$49.85M$54.59M-$2.58M-$87.88M-$1.82M$34.65M-$30.04M-$5.36M-$47.39K-$188.99K
    Financing cash flow$75.21M$622.00K$30.54M$180.66K$904.08K$47.07M$86.54M$286.14K$66.70M-$13.67K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$15.88M-$17.59M-$13.90M-$10.41M-$12.87M-$4.77M-$10.28M-$10.01M-$15.01M-$14.26M-$16.69M-$11.91M
    Capital expendituresN/AN/A$0$0$0$0$22.00K$4.00K$4.00K$150.00K$19.00K$1.22K
    Free cash flowN/AN/A-$13.90M-$10.41M-$12.87M-$4.77M-$10.30M-$10.01M-$15.01M-$14.40M-$16.70M-$11.91M
    Last 12 quarters

    Frequently Asked Questions About OVID

    What is Ovid Therapeutics' annual revenue?

    Ovid Therapeutics reported revenue of $7.25M for the fiscal year ended Dec 31, 2025.

    How fast is Ovid Therapeutics' revenue growing?

    Revenue was up 1181.3% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 69.0%.

    Is Ovid Therapeutics profitable?

    No. Ovid Therapeutics reported net income of -$17.41M for the fiscal year ended Dec 31, 2025, with a net margin of -240.1%.

    How much free cash flow does OVID generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$38.33M minus capital expenditures of $0 produced free cash flow of -$38.33M.

    How much debt does Ovid Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.43M and cash and equivalents of $13.15M.